Literature DB >> 30726968

The failure of the UK to tax adequately tobacco company profits.

J Robert Branston1,2, Anna B Gilmore2,3.   

Abstract

BACKGROUND: A key driver of the global tobacco epidemic is the massive profit earned from manufacturing tobacco products despite high levels of product taxation. Two of the four major Transnational Tobacco companies are based in the UK, where there is growing evidence of corporate tax avoidance by transnational firms and where there are calls for the industry to pay more towards the harms caused by tobacco products. OBJECTIVES/
METHODS: UK tobacco company profit and corporation tax data between 2009 and 2016 is obtained from publically available sources. The intention is not to perform a piece of forensic accounting but to establish the broad pattern of profit and taxation in order to inform consideration of tobacco product and firm taxation, and hence public health.
RESULTS: Very little profit based taxation has been paid in the UK despite high levels of reported profits, both in the domestic market and globally.
CONCLUSIONS: The UK needs better reporting and corporate taxation standards. Tobacco companies should be made to pay more profit based taxation, such as by extending the surcharge on corporation tax currently paid by UK banks, and by making sure companies pay appropriate taxes when reorganizing corporate structures.
© The Author(s) 2019. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  UK; corporation tax; profits; taxation; tobacco Industry

Year:  2020        PMID: 30726968      PMCID: PMC7044670          DOI: 10.1093/pubmed/fdz004

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  7 in total

1.  Differential Taxes for Differential Risks--Toward Reduced Harm from Nicotine-Yielding Products.

Authors:  Frank J Chaloupka; David Sweanor; Kenneth E Warner
Journal:  N Engl J Med       Date:  2015-08-13       Impact factor: 91.245

2.  Big tobacco, E-cigarettes, and a road to the smoking endgame.

Authors:  J Robert Branston; David Sweanor
Journal:  Int J Drug Policy       Date:  2015-12-29

Review 3.  Transforming the tobacco market: why the supply of cigarettes should be transferred from for-profit corporations to non-profit enterprises with a public health mandate.

Authors:  C Callard; D Thompson; N Collishaw
Journal:  Tob Control       Date:  2005-08       Impact factor: 7.552

4.  The case for OFSMOKE: how tobacco price regulation is needed to promote the health of markets, government revenue and the public.

Authors:  Anna B Gilmore; J Robert Branston; David Sweanor
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

5.  Follow the money: how the billions of dollars that flow from smokers in poor nations to companies in rich nations greatly exceed funding for global tobacco control and what might be done about it.

Authors:  Cynthia Callard
Journal:  Tob Control       Date:  2010-08       Impact factor: 7.552

6.  Global economic cost of smoking-attributable diseases.

Authors:  Mark Goodchild; Nigar Nargis; Edouard Tursan d'Espaignet
Journal:  Tob Control       Date:  2017-01-30       Impact factor: 7.552

7.  The case for Ofsmoke: the potential for price cap regulation of tobacco to raise £500 million per year in the UK.

Authors:  J Robert Branston; Anna B Gilmore
Journal:  Tob Control       Date:  2013-01-14       Impact factor: 7.552

  7 in total
  1 in total

1.  Industry profits continue to drive the tobacco epidemic: A new endgame for tobacco control?

Authors:  J Robert Branston
Journal:  Tob Prev Cessat       Date:  2021-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.